Previous 10 | Next 10 |
2023-07-26 09:33:07 ET While we normally talk about stocks that are trading sub-$5, seeing that this particular stock closed at $3.80 yesterday, we couldn’t help but bring it up this morning, regardless of how high it’s trading right now! A California-based %Biotech fi...
FREMONT, CA - ( NewMediaWire ) - July 26, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it has signed a term sheet to adva...
FREMONT, CA - ( NewMediaWire ) - July 24, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today announced a reverse stock split of its common ...
2023-07-06 09:12:03 ET ABVC BioPharma ( NASDAQ: ABVC ) said on Thursday that its CEO, Uttam Patil, had decided to forgo his salary. Patil had instead chosen to receive stock options as a part of his compensation package. Press Release For further details see...
FREMONT, CA - ( NewMediaWire ) - July 06, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the visionary new CEO of ABVC has selflessly c...
2023-06-26 11:07:25 ET ABVC BioPharma ( NASDAQ: ABVC ) has appointed Uttam Yashwant Patil as its new chief executive officer, the company said Monday. Patil's employment with ABVC began on June 23, the company said. Press Release . For furth...
FREMONT, CA - ( NewMediaWire ) - June 26, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the appointment of Dr. Uttam Yashwant Patil (Dr. Uttam) a...
FREMONT, CA, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in oncology/hematology, CNS, and ophthalmology, announced today that its wholly owned subsidiary, BioKey...
FREMONT, CA - ( NewMediaWire ) - June 12, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, neuropsychiatric conditions, and ophthalmology, today announced that the first subjec...
FREMONT, CA, June 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today a...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients. This new study will i...
FREMONT, CA - ( NewMediaWire ) - July 9, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that after successful Phase II c...
FREMONT, CA - ( NewMediaWire ) - July 02, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and it...